CNS Pharmaceuticals (CNSP) investor relations material

Executive summary

• Announced a new corporate strategy in March 2026, shifting focus from glioblastoma multiforme to broader innovative therapies and out-licensing legacy assets.

• Strategic transformation underway, shifting focus from a single asset to a diversified pipeline targeting serious diseases.

• Board expanded with expertise in business development and licensing to support new strategy, including appointment of Michal Fisher.

• Legacy clinical trial for Berubicin completed; out-licensing discussions ongoing for Berubicin and TPI 287.

• Leadership changes included the resignation of the CEO in December 2025 and appointment of new board members in 2026.

Financial highlights

• Net loss for Q2 2026 was $2.6 million, up 9% year-over-year; six-month net loss was $7.5 million, up 12.7%.

• Cash and cash equivalents as of June 30, 2026, were $20.0 million, up from $7.2 million at year-end 2025, due to a $22.5 million private placement.

• Operating expenses for Q2 2026 increased 12.1% year-over-year to $2.7 million, driven by higher G&A and R&D costs.

• General and administrative expenses rose to $1.5 million from $1.2 million year-over-year, mainly due to higher headcount.

• Working capital surplus of $18.2 million as of June 30, 2026.

Outlook and guidance

• Current cash resources and recent financing are expected to fund planned operations beyond twelve months from the reporting date.

• Plans to in-license or acquire new assets by year-end 2026 to expand the pipeline.

• Management actively evaluating business development opportunities while maintaining financial discipline.

• Future R&D expenses will depend on timing and nature of new asset acquisitions or in-licensing.

• Additional capital will be required for further development and commercialization activities.